Minibeam radiation for skin or soft tissue tumors
Part of Cancer, Skin clinical trials.
This trial tests a new type of radiation called minibeam therapy for people with skin or soft tissue cancers that have come back or spread. It's designed to help shrink tumors that standard treatments haven't worked well for, and it uses a special device to focus the radiation more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Has skin or soft tissue cancer that has come back or spread to other areas
- Life expectancy of at least 30 days
- Able to have follow-up visits at the study center for at least 30 days
- Willing to provide blood and tissue samples for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a radiation-emitting device (DaRT) to treat certain cancers on the skin, in the mouth, or in superficial soft tissues. You may qualify if you have a confirmed malignant tumor, enough body strength for treatment, and blood tests and pregnancy status that meet safety limits.
This trial tests a precise type of radiation that targets multiple tumor spots in a carefully planned way. It may help people with many metastatic (spread) solid tumors when standard treatments aren’t working or can’t be used.
This trial tests a radiation-emitting device placed near the tumor to treat certain malignant skin cancers that can be fully covered. It may help shrink or control the cancer at the skin site where the device is applied.
This Phase 1/2 study tests an “Auger molecular therapy” treatment that uses targeted radiation on certain advanced cancers that have spread to the skin. It may help shrink or control skin tumors where the lesion size and location fit the treatment device.
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
This study tests a very focused form of radiation for melanoma that has spread and has stopped responding to PD-1 (and sometimes CTLA-4) immunotherapy. It may help by shrinking progressing spots while keeping the immune treatment going.
Hear when a new Skin Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.